Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Bayer Healthcare and Sanofi Genzyme.

Medical Crossfire®: Individualizing Treatment in CRPC Based on Patient and Disease-Specific Factors

Release Date: October 14, 2021
Expiration Date: October 14, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in renowned experts in urology and prostate cancer will evaluate the efficacy, safety, and sequencing of therapies used for the management of castration-resistant prostate cancer (CRPC) across the disease spectrum, examine the factors that influence treatment decision-making, and assess strategies to monitor, mitigate, and manage treatment-related adverse events. Through case studies and dynamic debates, various evidence-based approaches to the personalized management of patients with CRPC will be put into clinical context.

This educational activity is an archive of a live virtual symposium held on September 27, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bayer Healthcare and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of prostate cancer (PC). Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with prostate cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Explain the biological mechanisms and diagnostic factors that distinguish CRPC from hormone-sensitive PC.
Evaluate safety and efficacy data from clinical trials that inform treatment sequencing in CRPC across the disease continuum.
Identify proactive strategies to monitor for and mitigate adverse events associated with systemic therapies for CRPC.
Apply patient-, disease-, and treatment-related factors to individualize optimal care strategies in CRPC.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Chair

Oliver Sartor, MD
Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Associate Dean for Oncology
Tulane University School of Medicine
New Orleans, LA

Disclosures: Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, TeneoBio; Consultant: Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien München, Janssen, Merck, Myovant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, TeneoBio, Telix, Theragnostics.

Faculty

Tomasz M. Beer, MD, FACP
Grover C. Bagby Endowed Chair for Prostate Cancer Research
Deputy Director
OHSU Knight Cancer Institute

Chief Medical Officer
CEDAR Professor of Medicine, Hematology & Medical Oncology
Director, Prostate Cancer Research Program
Portland, OR

Disclosures: Grant/Research Support: Paid to institution: Alliance Foundation Trials, Astellas Pharma, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc., Freenome, Grail Inc., Harpoon Therapeutics, Janssen Research & Development, Medivation Inc., Sotio, Theraclone Sciences/OncoResponse, Zenith Epigenetics; Consultant: Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squib, Constellation, Grail Inc., Janssen, Myovant Sciences, Pfizer, Sanofi, Clovis Oncology, Novartis, Tolero; Stock/Shareholder: Arvinas Inc., Salarius Pharmaceuticals.

Alicia K. Morgans, MD, MPH
Genitourinary Medical Oncologist
Medical Oncologist, Survivorship Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: Astellas, Bayer, Sanofi, Seattle Genetics; Consultant: Astellas, AstraZeneca, AAA, Bayer, Clovis, Dendreon, Lantheus, Myovant, Novartis, Pfizer, Myriad, Sanofi.

Fred Saad, MD, FRCS, FCAHS
Professor and Raymond Garneau Chair in Prostate Cancer, Department of Surgery/Urology
University of Montreal
Montreal, Canada

Disclosures: Grant/Research Support: Astellas, AstraZeneca, Bayer, Janssen, Myovant, Novartis, Pfizer, Sanofi; Consultant: Astellas, AstraZeneca, Bayer, Janssen, Myovant, Novartis, Pfizer, Sanofi.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.